Receipt date: 07/18/2008 10037341 - GAU: 1636

EXHIBIT A

of Supplemental Information Disclosure Statement filed July 15, 2008

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002 Group Art Unit: 1636 Examiner: D. Guzo

Form P1	'O -1	449 Substitute U.S. Department of Commerce Patent and Trademark Office	Application Number Filing Date	10/037,341 January 4, 20	002
		TION DISCLOSURE STATEMENT	First Named Inventor Art Unit Examiner Name	David Baltimo et al. 1636 D. Gazo Hibbe	
		377 100		75723-ZA/JPW,	/GJG
Examiner Initials	Cite No. ¹	NON PATENT LITERATURE DOC' Include name of the author (in CAPITAL LETTERS), title of the (book, magazine, journal, serial, symposium, catalog, etc.) date, pa and/or country where pub	e article (when approp ige(s), volume-issue nu	riate), title of the item mber(s), publisher, city	T ²
/C.H./	1	December 16, 2005 Condensed Deposit: Glimcher in Civil Case 02 CV 11280 Exhibits 1-13 attached with this This Information Disclosure Statement, not Laurie H. Glimcher [DDX 385 12/16] Review Article Drugs, (2004), 837-85 Opal 105]; Opal and Huber, Critical [DDX389 12/16/05]; Joyce et al., The Chemistry, (2001), 276:11199-11203 and Grinnell, Crit. Care Med, (2002) 12/16/05]; Brun-Buisson et al., JAMA [DDX392 12/16/05]; Joyce et al., The Chemistry, (2001), 276:11199-11203 Brueckmann et al., Inflamm. Res. (2012/16/05); Leeuwen et al., Crit Care 1077 [DDX395 12/16/05]; Derhaschnig 102:2093-2098 [DDX396 12/16/05]; Kai (2004), 21:222-229 [DDX397 12/16/05]; Care Med. (2004) 32Supp:S194-S201 [I	RWZ including ird Supplement amely: Curric 6/05]; Glick 59 [DDX388 15 Care, (2002 DDX390 12/10), 30:S288-S2A, (1995), 20 Journal of [DDX393 12/1004), 528-53 DM Med (2001) et al., Block of al., Block of [DDX]; Dhainar	g deposition intal culum Vitae and Opal, 2/16/05 &), 6:125-136 Biological 6/05]; Joyce 293 [DDX391 74:968-974 Biological 6/05]; 3 [DDX394 , 29:1074-od. (2003), Chock, l., Blood, ut, Crit	
/C.H./	2	Rule 26(A)(2) Rebuttal Report of The dated October 21, 2005 in Civil Case including Exhibits 1-71 attached with Supplemental Information Disclosure Patent No. 5,500,365, issued March al.; U.S. Patent No. 5,625,136, issued Koziel et al.; File History of U.S. filed April 6, 1995; U.S. Patent No. September 8, 1998, Baltimore et al.; 5,939,421, issued August 17, 1999, History of 06/946,365, filed December History of U.S. Serial No. 06/817,441986; U.S. Patent No. 6,060,310, issued Chung; File History of U.S. Serial November 13, 1991; U.S. Patent No. 6,2002, Baltimore et al.;	e 02 CV 11280 th this Four Statement, 19, 1996, Figued April 29 Serial No. 6. 5,804,374, U.S. Patent Palanki et aler 24, 1986; 41, filed James and May 9, 280. 07/791,896,410,516, is	O RWZ th namely: U.S. schhoff et , 1997, 08/418,266, issued t No. l.; File File nuary 9, 2000, Cho- 98, issued ssued June	
EXAMINER SIGNATURI		/Catherine Hibbert/	04/08/2009		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002

Exhibit A

10/037,341 Form PTO-1449 Substitute U.S. Department of Commerce Application Number Patent and Trademark Office Filing Date January 4, 2002 David Baltimore First Named Inventor et al. INFORMATION DISCLOSURE STATEMENT Art Unit 1636 (Use several sheets if necessary) Guzo Hibbert Examiner Name 75723-ZA/JPW/GJG Attorney Docket No. NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials No.1 (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. issued January 11, 2005, Gerlitz et al.; File History of U.S. Serial No. 07/155,207, filed February 12, 1988; File History of U.S. Serial No. 07/162,680, filed March 1, 1988; File History of U.S. Serial No. 07/280,173, filed December 5, 1988; File History of U.S. Serial No. 07/318,901, filed March 3, 1989; File History of U.S. Serial No. 07/341,436, filed April 21, 1989; Arruda et al., Blood (2005) 105:3458-3464; Kline et al., Int. J. Immunopharmac. (1984) 6:467-/C.H./ 473; Ballard et al., Cell (1990) 63:803-814; Bass et al., Proteins: Structure, Function & Genetics (1990) 8:309-314; Berns et al., Breast Cancer Research & Treatment (1984) 4:195-204; Boda et al., Folia Biologica (1987) 33:93-97; Bressler et al., Journal of Virology (1993) 67:288-293; Brown et al., Methods in Enzymology (1979) 68:109-151; Brown et al., Science (1995) 267:1485-1488; Cai et al., The Journal of Biological Chemistry (1997) 272:96-101; Cunningham and Wells, Science (1989) 244:1081-1085; Davis et al., Science (1991) 253:1268-1271; Du et al., Molecular Brain Research (2005) 136:177-188; Esslinger et al., The con Journal of Immunology (1997) 158:5075-5078; Curriculum t. Vitae of Thomas Robert Kadesch dated 4/26/05; Fenteany et al., Science (1995) 268:726-731; Fiedler et al., Am. J. Respir. Cell Mol. Biol. (1998) 19:259-268; Fujihara et al., The Journal of Immnology (2000) 165:1004-1012; Gallop et al., J. Of Medicinal Chemistry (1994) 37:1233-1251; Gehrt et al., The Journal of Antibiotics (1998) 51:455-463; Gesner et al., Journal of Cellular Physiology (1988) 136:493-499; Gill and Ptashne, Nature (1988) 334:721-724; |Haskill et al., Cell (1991) 65:1281-1289; Horuk R., Journal of Immunological Methods (1989) 119:255-258; Hoyos et al., Science (1989) 244:457-460; Kawamura et al. Gene Therapy (2001) 905-912; Khaled et al., Clinical Immunology (1998) 86:170-179; Krappmann et al., The EMBO Journal (1996) 15:6716-6726; Kumar et al., Oncogene (1998) 17:913-918; Lenardo and Baltimore, Cell (1989) 58:227-229; Lloyd et al., Nature (1991) 352:635-638; Logeat et al., The EMBO Journal (1991) 10:1827-1832; LyB et al., The Journal of

EXAMINER SIGNATURE

/Catherine Hibbert/

DATE CONSIDERED

04/08/2009

Biological Chemistry (1998) 273:33508-33516;

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute **U.S. Department of Commerce**

Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Application Number	10/037,341
Filing Date	January 4, 2002
First Named Inventor	David Baltimore
rirst Named inventor	et al.
Art Unit	1636
Examiner Name	D. Guzo Hibbert
Attorney Docket No.	75723-ZA/JPW/GJG

NON PATENT LITI	RATURE	DOCUMENTS
-----------------	--------	-----------

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2 Con t.	McKinney et al., The Journal of Biological Chemistry (1997) 272:22377-22380; McKnight and Kingsbury, Science (1982) 217:316-324; Meng et al., Proc. Natl. Acad. Sci. USA, (1999) 96:10403-10408; Morishita et al., Nature Medicine (1997) 3:894-899; Myers et al., Science (1986) 232:613-618; Nabel et al., Proc. Natl. Acad. Sci. USA, (1996) 93:15388-15393; Nicolau et al., Cell Fusion (1984) pp.254-267; Palombella et al., Proc. Natl. Acad. Sci. USA, (1998) 95:16741-15676; Ray et al., The Journal of Biological Chemistry (1995) 270:10680-10685; Reisine et al., Proc. Natl. Acad. Sci. USA, (1985) 82:8261-8265; Roberts K., Week in Review Desk (1985); Roozemond et al., Immunobiol. (1987) 176:35-46; Sawa et al., Circulation (1997) 96[suppl II]:II-280-II-285; Schindler et al., The Journal of Immunology (1990) 144:2216-2222; Scott and Smith, Science (1990) 249:386-390; Shakhov et al., J. Exp. Med. (1990) 171:35-47; Holden C., Science (1985) 230:302; Tomita et al., J. Hypertens (1998) 16:993-1000; Trepicchio and Krontiris, Nucleic Acids Research (1993) 21:977-985; Tung et al., Proc. Natl. Acad. Sci. USA, (1988) 85:2479-2483; PCT International Application No. WO 90/02809, International Publication Date March 22, 1990; PCT International Application Date March 22, 1990; PCT International Publication Date December 13, 1990;	
/C.H./	3	October 21, 2005 Rule 26(A)(2) Rebuttal Report Of Thomas R. Kadesch, Ph.D. in Civil Case 02 CV 11280 RWZ;	
/C.H./	4	February 12, 2001 Response and Amendment in U.S. Serial No. 08/464,364, ADL 0000843-0000853, Document 198, filed 02/03/2006, in Civil Case 02 CV 11280 RWZ;	
/C.H./	5	Davis et al., Science (1991) 253:1268-1271, Document 198, 02/03/2006, in Civil Case 02 CV 11280 RWZ;	
/C.H./	6	Haskill, et al., Cell (1991) 65:1281-12889, Document 198, filed 02/03/2006, in Civil Case 02 CV 11280 RWZ;	
EXAMINER SIGNATUR		/Catherine Hibbert/ 04/08/2009	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

10/037,341 Form PTO-1449 Substitute **U.S. Department of Commerce** Application Number January 4, 2002 Patent and Trademark Office Filing Date David Baltimore First Named Inventor et al. INFORMATION DISCLOSURE STATEMENT 1636 Art Unit (Use several sheets if necessary) Suzo Hibbert Examiner Name Attorney Docket No. 75723-ZA/JPW/GJG NON PATENT LITERATURE DOCUMENTS Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city Initials No. and/or country where published. /C.H./ March 3, 2004 Memorandum Of Decision And Order on claim construction; November 11, 2005 Reply Expert Report of Dr. Stephen /C.H./ Prescott, paragraphs 16-18; November 11, 2005 Reply Expert Report of Dr. Jeffrey /C.H./ Ravetch, paragraphs 6-9; November 11, 2005 Reply Expert Report Of Dr. Laurie H. 10 /C.H./ Glimcher, page 11 and 12; /C.H./ November 11, 2005 Rule 26(b)(2) Reply Report of David M. 11 Livingston, M.D., pages 17-18; November 22, 2005 Condensed Deposition of Stephen Prescott /C.H./ 12 in Civil Case 02 CV 11280 RWZ, page 226, line 24 - page 242, line 25 and page 262, line 9 - page 267, line 20; November 30, 2005 Condensed Deposition of Jeffrey V. 13 Ravetch in Civil Case 02 CV 11281 RWZ, page 40, line 8 -/C.H./ page 58, line 25; Trial Transcript - April 26, 2006 Jury Trial Day 12, Second /C.H./ 14 Session in Civil Case 02 CV 11281 RWZ, page 112, line 10 and page 124, line 16; CHARAFON FRAMINITATION OF DAIL FRACTIONS October 10, 2007 The Amgen Entities' Responses To /C.H./ 16 Whitehead's First Set of Interrogatories in Civil Action No. 06-259 (MPT);

EXAMINER SIGNATURE

/C.H./

/Catherine Hibbert/

(MPT);

DATE CONSIDERED

17 of Interrogatories (Nos. 1-15) in Civil Action No. 06-259

October 10, 2007 Wyeth's Responses To Whitehead's First Set

04/08/2009

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

EXAMINER SIGNATURE

/Catherine Hibbert/

Form P	ГО-1	449 Substitute U.S. Department of Commerc		10/037,341 January 4, 20	002
		Patent and Trademark Office	Filing Date	David Baltimo	
INFOD	илт	ION DISCLOSURE STATEMENT	First Named Inventor	et al.	Ore
		sheets if necessary)	Art Unit	1636	
(Ose seri	CI AI .	siects if necessary)	Examiner Name	D. Guse Hibbe	ert
			Attorney Docket No.	75723-ZA/JPW,	/GJG
		NON PATENT LITERATURE D	OCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title o (book, magazine, journal, serial, symposium, catalog, etc.) date and/or country where	f the article (when approp e, page(s), volume-issue nu		T ²
/C.H./	1 Ω	October 11, 2007 Wyeth's Second Seroduction of Documents And Things Harvard, MIT, and Whitehead in Civ(MPT);	et of Requests s (Nos. 22-101) To Ariad,	
/C.H./	19	October 15, 2007 The Amgen Entition First Set of Interrogatories in Compt);	es' Responses ivil Action No	to MIT's . 06-259	
/C.H./	20	October 15, 2007 The Amgen Entition First Set of Interrogatories in Compt);			
/C.H./	21	October 15, 2007 The Amgen Entities Fourth Set of Requests For Product Action NO. 06-259 (MPT);	es' Responses tion of Docume	to Ariad's nts in Civil	
/C.H./	22	October 31, 2007 Wyeth's Fourth Se Responses And Objections To Ariad Interrogatories (Nos. 1-25) in Ci-	's First Set o	f	
/C.H./	23	October 31, 2007 Ariad's And The And Objections To Wyeth's First Section No. 06-259 (MPT);	Institutions' et of Interrog	Responses atories in	
/C.H./	24	October 31, 2007 Ariad's And The And Objections To Wyeth's First So Production of Documents And Thing: 259 (MPT);	et of Requests	For	
/C.H./	25	November 6, 2007 Defendant And Con Ariad's Sixth Set of Requests For Entities in Civil Action No. 06-2	Production To	intiff The Amgen	
/C.H./	26	November 7, 2007 Wyeth's First Seadmission (Nos. 1-160) To Ariad, Whitehead in Civil Action No. 06-2	Harvard, MIT,	for and	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

04/08/2009

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Application Number	10/037,341
Filing Date	January 4, 2002
First Named Inventor	David Baltimore
Art Unit	1636
Examiner Name *	D. Guzo Hibbert
Attorney Docket No.	75723-ZA/JPW/GJG

1	NO	N	P	Δ	T	F	N	т	ı	ľ	Г	F	L	2 /	١.	Т	I	R	1	7.	n	C	1	T	N	И	F	:N	J٦	Г٩	3

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
/C.H./	27	November 7, 2007 The Amgen Entities' Responses To Ariad's Fifth Set of Requests For Production of Documents in Civil Action No. 06-259 (MPT);					
/C.H./	28	November 7, 2007 Wyeth's Third Set of Requests For Production of Documents And Things (Nos. 101-109) To Ariad, Harvard, MIT, and Whitehead in Civil Action No. 06-259 (MPT);					
/C.H./		November 8, 2007 Wyeth's Responses To Ariad's Third Set of Requests For Production of Documents (Nos. 108-121) in Civil Action No. 06-259 (MPT);					
/C.H./	30	November 12, 2007 The Amgen Entities' Responses To Ariad's Third Set of Interrogatories in Civil Action No. 06-259 (MPT);					
/C.H./		ovember 12, 2007 Wyeth's Responses And Objections To Ariad nd The Institutions' Second Set of Interrogatories (Nos. 6-29) in Civil Action No. 06-259 (MPT);					
/C.H./	32	ovember 13, 2007 Defendant And counterclaim Plaintiff riad's Fourth Set of Requests For Production of Documents nd Things to Wyeth in Civil Action No. 06-259 (MPT);					
/C.H./	33	November 15, 2007 Ariad's And The Institutions' Responses And Objections To Wyeth's Second Set of Interrogatories in Civil Case No. 06-259 (MPT);					
/C.H./	34	November 15, 2007 The Amgen Entities' Second Set of Requests For Admission Directed To Ariad And the Institutions in Civil Action No. 06-259 (MPT);	_				
/C.H./	35	November 15, 2007 The Amgen Entities' Third Set of Requests For Production of Documents And things Directed To Ariad And The Institutions in Civil Action No. 06-259 (MPT);					
EXAMINER SIGNATUR		/Catherine Hibbert/ 04/08/2009					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

INFORMA (Use severa Examiner Initials' No	ATION al sheet lite (book 259) Der 21, 20 re 10	vember 15, d Objection of (MPT); position T, 2007, Ammpany, Rocffmann-La	Patent an URE STAT Ty) NON PAT Tauthor (in CA rnal, serial, syr 2007 A Ons To Wy For Docum	FENT LITERAT PITAL LETTER mposium, catalog, and/or countr riad's And yeth's Sec ments And	CURE DOC S), title of the etc.) date, party where public d the Internal Set	e article (when a ge(s), volume-is ished. nstitution	et No.	et al. 1636 D. Guzo Hibbe 75723-ZA/JPW, riate), title of the item nber(s), publisher, city	rt /GJC	
Examiner Initials No	Nov. And Pro 259 Der 21, Corr Hots Dis	clude name of the ok, magazine, jour vember 15, d Objection oduction for (MPT); position T, 2007, Ammpany, Rooffmann-La	NON PAT author (in CA rnal, serial, syr 2007 A ons To W for Docum Transcrip	FENT LITERAT PITAL LETTER mposium, catalog, and/or countr riad's And yeth's Sec ments And	S), title of the etc.) date, pary where public the Incond Set	Art Unit Examiner Nam Attorney Dock UMENTS e article (when a ge(s), volume-is ished. astitution of Requirements	et No.	et al. 1636 75723-ZA/JPW, riate), title of the item mber(s), publisher, city	rt /GJC	
Examiner Initials No	Nov. And Pro 259 Der 21, Corr Hots Dis	clude name of the ok, magazine, jour vember 15, d Objection oduction for (MPT); position T, 2007, Ammpany, Rooffmann-La	NON PAT author (in CA rnal, serial, syr 2007 A ons To W for Docum Transcrip	FENT LITERAT PITAL LETTER mposium, catalog, and/or countr riad's And yeth's Sec ments And	S), title of the etc.) date, pary where public the Incond Set	Art Unit Examiner Nam Attorney Dock UMENTS e article (when a ge(s), volume-is ished. astitution of Requirements	et No.	et al. 1636 D. Guzo Hibbe 75723-ZA/JPW, riate), title of the item nber(s), publisher, city	/GJC	
Examiner Initials No	Nov. 259 Dep 21, 20 Propose 10 Propose 21, 21, 22 Propose 21, 22 P	clude name of the ok, magazine, jour vember 15, d Objection oduction for (MPT); position T, 2007, Ammpany, Rooffmann-La	NON PAT author (in CA rnal, serial, syr 2007 A ons To Wy for Docum Transcrip	nposium, catalog, and/or countr riad's And yeth's Sec ments And	S), title of the etc.) date, pary where public the Incond Set	Examiner Nam Attorney Dock UMENTS e article (when a ge(s), volume-is ished. nstitution of Requirements	et No.	75723-ZA/JPW,	/GJC	
/C.H./ 31	Nov And Pro 259 Der 21, Cor Hots	vember 15, d Objection of (MPT); position T, 2007, Ammpany, Rocffmann-La	author (in CA rnal, serial, syr 2007 A ons To W For Docur	nposium, catalog, and/or countr riad's And yeth's Sec ments And	S), title of the etc.) date, pary where public the Incond Set	Attorney Dock UMENTS e article (when a ge(s), volume-is ished. nstitution of Requirements	appropr	75723-ZA/JPW,	/GJG	
/C.H./ 31	Nov And Pro 259 Der 21, Cor Hots	vember 15, d Objection of (MPT); position T, 2007, Ammpany, Rocffmann-La	author (in CA rnal, serial, syr 2007 A ons To W For Docur	nposium, catalog, and/or countr riad's And yeth's Sec ments And	S), title of the etc.) date, pary where public the Incond Set	UMENTS e article (when a ge(s), volume-is ished. nstitution of Requ	appropr	riate), title of the item nber(s), publisher, city	T ²	
/C.H./ 31	Nov And Pro 259 Der 21, Cor Hots	vember 15, d Objection of (MPT); position T, 2007, Ammpany, Rocffmann-La	author (in CA rnal, serial, syr 2007 A ons To W For Docur	nposium, catalog, and/or countr riad's And yeth's Sec ments And	S), title of the etc.) date, pary where public the Incond Set	e article (when a ge(s), volume-is ished. nstitution	ons'	Responses		
/C.H./ 31	Nov And Pro 259 Der 21, Cor Hots	vember 15, d Objection of (MPT); position T, 2007, Ammpany, Rocffmann-La	2007 Asons To Western Documents	mposium, catalog, and/or countr riad's And yeth's Sec ments And	etc.) date, pa y where publ d the In cond Set	ge(s), volume-is ished. nstitutic t of Requ	ons'	Responses		
/C II /	Der 21, Cor Hois	d Objection oduction for the second of the s	ons To Wy for Docur Transcrip	yeth's Sec ments And	cond Set	of Requ	ons'	Responses		
/C.H./	21, Cor Hot Dis	, 2007, Am mpany, Roc ffmann-La	ngen. Ind	nt of D=		in Civil	lests L Act	s For tion No. 06-		
	No.	eposition Transcript of Dr. Thomas R. Kadesch dated June 1, 2007, Amgen, Inc. v. F. Hoffmann-La Roche Ltd., a Swiss ompany, Roche Diagnostics GmbH, a German Company, and offmann-La Roche, Inc., A New Jersey Corporation, U.S. istrict Court, District of Massachusetts, in Civil Action o. 05-12237 WGY;								
/C.H./	Ar: 88 Mas Ins	October 11, 2007 Wyeth's Second Set of Interrogatories To Ariad, The President And Fellows of Harvard College, The Massachusetts Institute of Technology, And The Whitehead Institute For Biomedical Research in Civil Action No. 06-259 (MPT);								
/C.H./ 3	39 Ins	stitutions	s' Second	unterclaim d Set of I -259 (MPT)	Interro	iffs Ari gatories	lad's To W	s And The Vyeth in		
/C.H./ 4 (0 Ins	stitutions	s' Third	unterclaim Set of In ction No.	nterroga	atories T	lad's	s And The ne Amgen		
/C.H./ 4:	Ari 1 Mas Ins	iad, The F ssachusett	President Is Instit	eth's Thir t And Fell tute of Te dical Rese	lows of echnolog	Harvard Jy, And T	Coll The W	lege, The		
/C.H./ 42	2 Int	terrogator	ries Dire	mgen Entit ected To A -259 (MPT)	Ariad Ar	nird Set nd the In	of nstit	cutions in		
/C.H./	3 the	e litigati armaceutio	on capt: cals, Inc	ioned <i>Amge</i>	en, Inc.	et al. District	v. A	Ph.D. in Ariad art for the		
EXAMINER SIGNATURE		/Catherine H	libbert/	DATE CONS	SIDERED	04/08/2009				

and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant

is to place a checkmark here if English language Translation is attached.

EXAMINER

SIGNATURE

/Catherine Hibbert/

					rage o or	- 10				
Form P	ΓΟ-1	449 Substitute	U.S. Department of Commerce	Application Number	10/037,341					
		11) Substitute	Patent and Trademark Office	Filing Date	January 4, 20	002				
INFOR	N # A 7F	TON DIGGLOSI		First Named Inventor	David Baltime					
			URE STATEMENT	Art Unit	1636					
(Use sev	erai	sheets if necessar	ry)	Examiner Name	B. Gwae Hibbe	ert				
				Attorney Docket No.	75723-ZA/JPW					
			NON PATENT LITERATURE DOC	•	<u> </u>					
Examiner Initials	Cite No. ¹		e author (in CAPITAL LETTERS), title of the irnal, serial, symposium, catalog, etc.) date, p and/or country where pul	age(s), volume-issue nu		T ²				
/C.H./	44	Whitehead, I P.30(b)(6), captioned Au Inc., et al	ntities' 5 th Notice of De Harvard and MIT Pursuant dated January 25, 2008, mgen, Inc. et al. v. Ari ., U.S. District Court f A No. 06-259-MPT;	to Fed. R.C in the liti	iv. gation <i>ticals,</i>					
/C.H./	45	on Amgen's l ARIAD's Cou <i>Inc. et al.</i>	anuary 31, 2008 Memorandum Order of the Hon. Judge Thynge n Amgen's Motion to Amend and Supplement Their Reply to RIAD's Counterclaims in the litigation captioned Amgen, nc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. istrict Court for the District of Delaware, CA No. 06-259-PT;							
/C.H./	46	Ph.D. in the Ariad Pharm	2008 Expert Report of Je litigation captioned Accuticals, Inc., et al.	Amgen, Inc. e , U.S. Distr	t al. v. ict Court					
/C.H./	47	the litigat Pharmaceuti	2008 Expert Report of Rion captioned Amgen, Inc. als, U.S. Delaware, CA No. 06-259	c. et al. v. District Co	Ariad					
/C.H./	48	October 21, 2005 Rule 26(A)(2) Rebuttal Report of Thomas R. Kadesch, Ph.D. in the litigation captioned Ariad Pharmaceuticals, Inc. et al. v. Eli Lilly and Co., U.S. District Court for the District of Massachusetts, CA No. 02 CV 11280 RWZ;								
/C.H./	49	Kadesch in	07 Deposition Transcript the litigation captioned Roche Ltd., et al., U.S	d Amgen, Inc.	v. F.					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

04/08/2009

District of Massachusetts, CA No. 0512237 WGY;

	1449 Substitute U.S. Department of Comm	nerce Application Number	10/037,341	
	Patent and Trademark O		January 4, 20	002
	• 1	First Named Inventor	David Baltimo	ore
INFORMAT	TION DISCLOSURE STATEMENT		et al.	
(Use several	sheets if necessary)	Art Unit	1636	and a
		Examiner Name	D. Guzo Hibbe	
		Attorney Docket No.	75723-ZA/JPW,	/606
	NON PATENT LITERATUR	E DOCUMENTS		
Examiner Cite No.1	1 \ \) date, page(s), volume-issue nu	riate), title of the item mber(s), publisher, city	T ²
/C.H./	November 6, 2007 Transcript of Patricia Granahan, Sc.D., pgs. Action No. 06-259 (MPT), include 08/464,364 (Pat. No. 6,410,516) Dep. Exh. 195; 2) 08/463,397 (Pariad Plaintiffs Dep. Exh. 196] Ariad Plaintiffs Dep. Exh. 197]; Ariad Plaintiffs Dep. Exh. 198] Ariad Plaintiffs Dep. Exh. 199] Ariad Plaintiffs Dep. Exh. 200] Ariad Plaintiffs Dep. Exh. 201] Ariad Plaintiffs Dep. Exh. 201] Ariad Plaintiffs Dep. Exh. 202] Exhibits 1-17 which are attached Information Disclosure Statement of 07/162,680 [inc. Tabs 1-29] November 14, 1988 correspondent (Granahan Exh. 2); 3) Declaration U.S. Serial No. 07/318,901 (Graffederal Regulations (Granahan Exh. 2); 3) Peclaration Granahan Exh. 6); 7) Manual of (Granahan Exh. 6); 7) Manual of (Granahan Exh. 6); 7) Manual of (Granahan Exh. 7); 8) WO 87/041 Redacted front sheet; Notice In Communication of the Internation Designated Offices issued under sentence inc. WO 89/08147 (Granahan Exh. 1) EP 0 407 411 B1 (Granahan Exh. 1) EP 0 407 411 B1 (Granahan Exh. 1) Redacted; 14) Redacted; 15) Red Redacted	1-235 & A.1-A.23 ling i) file hist [Amgen v. Ariad Pat. No. 6,150,09 ; 3) 08/418,266 4) 07/341,436 [; 5) 06/946,365 ; 6) 07/318,901 ; 7) 07/280,173 ; 8) 07/791,898 and, ii) deposited with this Support, namely: 1) file (Granahan Exh. 1) the from Patricia con for patent apparance of Patricia Granahan (Granahan Exh. 4); 5) Augustanahan (Granahan Exh. 4); 5) Augustanahan (Granahan Exh. 5) (Granahan Exh. 6) (Granahan Exh. 9); 10 (Granahan Ex	, in Civil ory of: 1) Plaintiffs 0) [Amgen v. tion lemental le history }; 2) Granahan plication) Code of t 10, 1990 Exh. 5); 6) nahan g Procedure . 8}; 9) icant of to the) first) Redacted; acted; 13)	
/C.H./ 51	November 7, 2007 Transcript of Lisa Marie Treannie, pgs. 1-130 No. 06-259 (MPT), including depare attached with this Suppleme Statement, namely: 1) January 1 Kiyoshi Asamura {Treannie Exh. 1996 correspondence from Lisa W 7-07}; 3) March 17, 1997 correspondence Exh. 3, 11-7-07};	O & A.1-A.13, in cosition Exhibits ental Information 8, 1996 correspo 1, 11-7-07; 2)	Civil Action 1-6 which Disclosure ndence from February 2, Exh. 2, 11-	
EXAMINER SIGNATURE	/Catherine Hibbert/	04/08/2009		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

EXAMINER SIGNATURE

/Catherine Hibbert/

Form P1	ro-1	449 Substitute U.S. Department of Commerce	Application Number	10/037,341	
		Patent and Trademark Office	Filing Date	January 4, 20	002
INFORN	лат	ION DISCLOSURE STATEMENT	First Named Inventor	David Baltimo et al.	ore
		sheets if necessary)	Art Unit	1636	
(Osc scr	. 41	sheets it necessary)	Examiner Name	D: Gwzo Hibbe	rt
			Attorney Docket No.	75723-ZA/JPW,	/GJC
		NON PATENT LITERATURE DOC	IIMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the (book, magazine, journal, serial, symposium, catalog, etc.) date, pa and/or country where pub.	e article (when approp age(s), volume-issue nu	riate), title of the item mber(s), publisher, city	T ²
/C.H./	Con	4) correspondence from Patricia Gran 11-7-07}; 5) July 8, 1997 correspond Warren {Treannie Exh. 5, 11-7-07}; 8 817,441 inc. Tabs 1-28 {Treannie Exh	nahan {Trean dence from L and 6) U.S.	isa M. Serial No.	
/C.H./	52	November 9, 2007 (Draft Transcript) Vincent, in Civil Action No. 06-259	of Matthew (MPT);	Perry	
/C.H./	53	November 13, 2007 Transcript of Vide David L. Berstein, Ph.D., pgs. 1-32. Action No. 06-259 (MPT) including dowhich are attached with this Suppler Disclosure Statement, namely: 1) Wyer Deposition Pursuant to Fed. R. Civ. Harvard, MIT, And Whitehead (Berstein November 5, 2007 correspondence from (Berstein Exh. 2, 11-13-07); 3) Many Procedure (Berstein Exh. 3, 11-13-07) June 17, 1997 correspondence from LEXh. 5, 11-13-07); 6) September 15, from Lisa Warren (Berstein Exh. 6, 8) February 17, 1998 correspondence (Berstein Exh. 8, 11-13-07); 9) Not (Berstein Exh. 9, 11-13-07); 10) And Memorandum from Patricia Granahan (107); 11) May 15, 2000 correspondence (Berstein Exh. 11, 11-13-07); 12) Reference (Berstein Exh. 11, 11-13-07); 12) Reference (Berstein Exh. 11, 11-13-07); 13, Redacted; 18, 11-13-07); 14) Redacted; 18, 11-13-07); 14) Redacted;	4 & A.1-A.30 eposition Ex mental Infor th's First N P. 30(b)(6) in Exh. 1, 1 m Nathan Low ual of Paten 7); 4) Reda isa Warren { 1997 corres 11-13-07); 7 from Patric ice of Allow ugust 30, 19 Berstein Exh e from Harve edacted; 13) ia Granahan	, in Civil hibits 1-16 mation otice of To Ariad, 1-13-07}; 2) enstein t Examining cted; 5) Berstein pondence) Redacted; ia Granahan ance 94 . 10, 11-13- y Berger December {Berstein	
/C.H./	54	November 29, 2007 Transcript of Depo Volume I, pgs. 2-150 & A.1-A.16 in (MPT);	osition of L Civil Action	aurie Allen, No. 06-259	
/C.H./	55	November 30, 2007 Transcript of Depo Volume II, pgs. 151-271 & A.1-A.13 259 (MPT);	osition of L in Civil Act	aurie Allen, ion No. 06-	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

04/08/2009

10/037,341 Form PTO-1449 Substitute U.S. Department of Commerce **Application Number** January 4, 2002 Patent and Trademark Office Filing Date David Baltimore First Named Inventor et al. INFORMATION DISCLOSURE STATEMENT 1636 Art Unit (Use several sheets if necessary) Gweo Hibbert Examiner Name 75723-ZA/JPW/GJG Attorney Docket No. NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city Initials No.1 and/or country where published. December 14, 2007 Transcript of Videotaped Deposition of /C.H./ 56 Harvey J. Berger, M.D., pgs. 1-146 & A.1-A.17 in Civil Action No. 06-259 (MPT); December 12, 2007 Transcript of Videotaped Deposition of /C.H./57 Lita Nelsen, pgs. 2-222 & A.1-A.23 in Civil Action No. 06-259 (MPT); December 18, 2007 Transcript of Deposition of Isabelle /C.H./ 58 Clauss, Volume I, pgs. 1-100 & A.1-A.10 in Civil Action No. 06-259 (MPT);February 22, 2008 Expert Report of David M. Livingston, /C.H./ M.D., in Civil Action No. 06-259 (MPT); February 22, 2008 Rebuttal Report of Jeffrey V. Ravetch, /C.H./ M.D., Ph.D., in Civil Action No. 06-259 (MPT); /C.H./ February 22, 2008 Rebuttal Expert Report of Randolph Wall, 61 Ph.D., in Civil Action No. 06-259 (MPT); March 7, 2008 Reply Expert Report of Warner Craig Greene, /C.H./ M.D., Ph.D., in Civil Action No. 06-259 (MPT); December 11, 2007 Amgen Entities' first Amended Reply to /C.H./ 63 Ariad, Harvard, MIT, And Whitehead's Amended Counterclaims, in Civil Action No. 06-259 (MPT); January 22, 2008 Telephone Conference before Mary Pat /C.H./ 64 Thynge, U.S. Magistrate Judge, in Civil Action No. 06-259 (MPT); February 8, 2008 Defendants-Counterclaim-Plaintiffs Ariad's /C.H/ And The Institutions' Memorandum of Law In Support of Their

EXAMINER /Catherine Hibbert/ DATE CONSIDERED 04/08/2009

(MPT);

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Motion To Amend Counterclaims, in Civil Action No. 06-259

Form P	Γ Ο-1	449 Substitute U.S. Department of Commerce	Application Number	10/037,341		
		Patent and Trademark Office	Filing Date	January 4, 20	002	
INFORM	м а т	ION DISCLOSURE STATEMENT	First Named Inventor	David Baltimo et al.	ore	
		sheets if necessary)	Art Unit	1636		
(OSE SEV	CI AI	sheets if hecessary)	Examiner Name	D. Gwao Hibbe	rt	
			Attorney Docket No.	75723-ZA/JPW,	/GJG	
		NON DATENT LITED ATLINE DOC				
Examiner Initials	Cite No.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	he article (when approp page(s), volume-issue nu	oriate), title of the item mber(s), publisher, city	T ²	
/C.H./	66	February 8, 2008 Declaration of David Greenwald In Support of Defendants-Counterclaim-Plaintiffs Ariad's And The institutions' Motion to Amend Counterclaims, in Civil Action No. 06-259 (MPT);				
/C.F		March 7, 2008 Defendants-Counterclaim-Plaintiffs Ariad's And The Institutions; Reply Memorandum In Support of Their Reply Memorandum in Support of Their Motion to Amend Counterclaims, Civil Action No. 06-259 (MPT);				
/C.H./	68	February 22, 2008 Expert Report of James Mark Jackson, M.D., in Civil Action No. 06-259 (MPT);				
/C.H.	/69	February 20, 2008 Condensed Transcript of Harvey Berger in the litigation captioned Amgen, Inc. Et al. v. Ariad Pharmaceuticals, Inc. et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT;				
/C.H./	70	March 7, 2008 Reply Expert Report of Randolph Wall, Ph.D. in the litigation captioned Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT;				
/C.H./	71	February 20, 2008 Condensed Transcript of Harvey Berger in the litigation captioned Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT;				
/C.H./	72	March 5, 2008 Reply Expert Report of Jeffrey M. Ravetch, Ph.D. in the litigation captioned Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT;				
/C.H./	73	October 30, 2007 Memorandum In Support of Eli Lilly And Company's Motion For Relief From Judgment Under Fed. R. Civ. P. 60(b) And for Additional Discovery, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

04/08/2009

/Catherine Hibbert/

EXAMINER SIGNATURE

Form P	Γ O -1	449 Substitute U.S. Department of Commerce	Application Number	10/037,341		
	_	Patent and Trademark Office	Filing Date	January 4, 20		
			First Named Inventor	David Baltimo	ore	
		ION DISCLOSURE STATEMENT		et al. 1636		
(Use sev	eral :	sheets if necessary)	Art Unit Examiner Name	P: Guzo Hibbe	rt	
			Attorney Docket No.	75723-ZA/JPW,		
				73723 2A701W	7 000	
Examiner	Cite	NON PATENT LITERATURE DOC		rioto) title of the item	T ²	
Initials	No.					
/C.H <i>.)</i>	74	November 15, 2007 Plaintiffs' Opposition To Lilly's Renewed Motion For Judgment As A Matter of Law Or, In The Alternative, A New Trial, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;				
/C.H./	75	December 5, 2007 Opposition To Eli Lilly And Company's Motion For Relief From Judgment Under Fed. R. Civ. P. 60(b) (Redacted version of document filed under seal), including Exhibits 1-7, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;				
/C.H./	76	December 13, 2007 Reply In Support of Defendant's Renewed Motion For Judgment As a Matter of Law Or, In the Alternative, A New Trial, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;				
/C.H./	77	December 26, 2007 Sur-Reply In Support of Plaintiff's Opposition To Defendant's Renewed Motion For Judgment As a Matter Of Law Or, In The Alternative, A New Trial, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;				
/C.H./	78	February 8, 2008 Notice Of Supplemental Authority, including attachment, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;				
/C.H	79	March 10, 2008 Notice of Appeal, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ;				
/C.H./	80	March 18, 2008 Notice of Docketing, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co, U.S. District Court for the District of Massachusetts, in Civil Action No. 02-11280 RWZ				
EXAMINER SIGNATUR		/Catherine Hibbert/	04/08/2009			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute **U.S. Department of Commerce** Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

	· · · · · · · · · · · · · · · · · · ·			
Application Number	10/037,341			
Filing Date	January 4, 2002			
First Name 1 I	David Baltimore			
First Named Inventor	et al.			
Art Unit	1636			
Examiner Name	D. Guzo Hibbert			
Attorney Docket No.	75723-ZA/JPW/GJG			

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/C.H./	81	Index of Civil Docket For Case No.: 1:02-cv-11280-RWZ starting from July 6, 2007, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts;				
/C.H./		April 25, 2008 Defendants-Counterclaim-Plaintiffs' Opening Brief on Claim Construction, U.S. District Court for the District of Delaware, CA No. 06-259-MPT;				
/C.H./		April 25, 2008 The Amgen Entities' Brief In Support of Their Motion For Summary Judgment of Noninfringement of U.S. Patent No. 6,410,516, U.S. District Court for the District of Delaware, in Civil Action No. 06-259 (MPT) Confidential Filed Under Seal;				
/C.H./	8.4	April 25, 2008 The Amgen Entities' Brief In Support of Their Motion to Preclude Ariad's Proffered Experts on Willfulness and Inequitable Conduct From Opining on Intent, State of Mind, and Other Matters, U.S. District Court for the District of Delaware, in Civil Action No. 06-259 (MPT) Public Version Confidential Material Omitted;				
/C.H./	85	April 25, 2008 The Amgen Entities' Brief In Support of Their Daubert Motion To Preclude Certain Unsupported and Unreliable Opinions of Dr. Ryan Sullivan Relating to Damages, U.S. District Court for the District of Delaware, in Civil Action No. 06-259 (MPT) Public Version Confidential Material Omitted;				
/C.H./		April 25, 2008 The Amgen Entities' Brief In Support of Its Daubert Motion To Preclude Certain Proffered Opinions of Dr. Jeffrey V. Ravetch Relating to Written Description and Inherent Anticipation, U.S. District Court for the District of Delaware, in Civil Action No. 06-259 (MPT);				
/C.H./	Ω7	April 25, 2008 Memorandum In Support of Defendants- Counterclaim-Plaintiffs' Motion for Partial Dismissal For Lack of Subject Matter Jurisdiction, U.S. District Court for the District of Delaware, CA No. 06-259-MPT				
EXAMINER SIGNATUR		/Catherine Hibbert/ DATE CONSIDERED 04/08/2009				

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PT	'O-1	449 Substitute	U.S. Depart	tment of Comme	rce	Application Number		
			•	Trademark Offic		Filing Date	January 4, 20	
INFORMATION DISCLOSU (Use several sheets if necessar			HDF STATE!	IDF STATEMENT		First Named Inventor	David Baltimo et al.	ore
				METAI		Art Unit	1636	
(030 00	/ B	sheets it necessa.	19,			Examiner Name	D. Guz o Hibbe	rt
						Attorney Docket No.	75723-ZA/JPW,	/GJC
			NON PATE	NT LITERATURE I	DOCI	UMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item					T ²	
/C.H./	88	7						
/C.H./	89	June 19, 2008 Transcript of Claim Construction Hearing in the litigation captioned Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT						
				·				
EXAMINER		Catherine		1		04/08/2009		
and not consi	R: Ini	itial if citation considered	l, whether or not citat m with next commun	nication to applicant, 'App	ith MPE	EP 609: Draw line through	th citation if not in conformation number (optional). ² Ap	ance